Cardioprotection of rat heart myocytes with amifostine (Ethyol®) and its free thiol, WR-1065, in vitro

European Journal of Cancer

Volumn 32, Issue SUPPL. 4, 1996, Pages

  Dorr, R T ^a,b   Lagel, K ^c   McLean, S ^b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c LOCKHEED MARTIN   (United States)

Author keywords

amifostine; anthracyclinase; cardiotoxicity; chemoprotection; doxorubicin; sulfhydryls

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; AMIFOSTINE; DOXORUBICIN; GLUTATHIONE;

ANIMAL CELL; ARTICLE; CARDIOTOXICITY; CONTROLLED STUDY; HEART MUSCLE CELL; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT;

AMIFOSTINE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL CULTURE TECHNIQUES; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART; MALE; MERCAPTOETHYLAMINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0029906872     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00314-0     Document Type: Article

References (45)

1. The anthracycline antineoplastic drugs
2. Inhibition of DNA and RNA metabolism by daunorubicin and adriamycin in L1210 mouse leukemia
3. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II
4. Qualitative and quantitative aspects of intercalator-induced DNA strand breaks
5. Generation of free radicals of quinone group containing anticancer chemicals in NADPH-microsome system as evidenced by initiation of sulfite oxidation
6. Adriamycin and its iron (III) and copper (II) complexes
7. Further studies on the generation of reactive oxygen species from activated anthracyclines and the relationship to cytotoxic action and cardiotoxic effects
8. Differential effects of anthracycline drugs on rat heart and liver microsomal reduced nicotinamide adenine dinucleotide phosphate-dependent lipid peroxidation
9. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical
10. Hydroperoxide metabolism in mammalian organs
11. Adriamycin chemotherapy: efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule
12. Risk factors for doxorubicin-induced congestive heart failure
13. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood
14. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin
15. Adriamycin: a new anticancer drug with significant clinical activity
16. Prevention of doxorubicin cardiac toxicity in the mouse by N-acetylcysteine
17. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response
18. Reduction of chronic doxorubicin cardiotoxity in dogs by pretreatment with (±)-1,2-bis (3, 5-dioxopiperazinyl)propane (ICRF-187)
19. Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat
20. Amelioration of chronic anthracycline cardiotoxicity by ICRF-187 and other compounds
21. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer
22. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer
23. Creatinine phosphokinase and cardiotoxicity in adriamycin chemotherapy and its modification by WR-1065
24. WR-2721 chemoprotection of doxorubicin toxicity in mice
25. In vitro study on the antioxidant activities of amifostine (WR-2721)
26. In vitro rat myocyte cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratios
27. Development of tumor cell lines
28. Assay of picomole amounts of ATP, ADP and AMP using the luciferase enzyme system
29. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
30. Pharmacokinetics of WR-2721
31. Pharmacologic studies of anticancer drugs with the human tumor stem cell assay
32. Comparison of cytotoxicity in heart cells and tumor cells exposed to DNA intercalating agents in vitro
33. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues
34. Radioprotection of tumor and normal tissues by thiophosphate compounds
35. Pilot trial of cisplatin, radiation, and WR2721 in carcinoma of the uterine cervix: a New York Gynecologic Oncology Group study
36. Phase I controlled trials of WR-2721 and cyclophosphamide
37. WR-2721 protects against the hematologic toxicity of cyclophosphamide: a controlled phase II trial
38. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma
39. Phase I study of WR-2721 and carboplatin
40. Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-aminopropylamino)-ethylphosphorothioic acid
41. Uptake of WR-2721 derivatives by cells in culture: identification of the transported form of the drug
42. Pharmacokinetics of WR-1065 in mouse tissue following treatment with WR-2721
43. Effect of doxorubicin on glutathione and glutathione-dependent enzymes in cultured rat heart cells
44. Anthracycline cardioprotection by amifostine (WR-2721) and its active metabolite (WR-1065) in vitro
45. Dephosphorylation of WR-2721 with mouse tissue homogenates